Matches in SemOpenAlex for { <https://semopenalex.org/work/W629160261> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- W629160261 abstract "1 Independent Biopharmaceutical Companies and Their Specialization in Drug Discovery Technologies.- 1.1 Drug Discovery in Research and Development Pipelines.- 1.2 Growth Problems Generated by R&D Duration.- 1.3 Consequences of Human Genetic Research on Drug Discovery.- 2 Model Structure for High-Technology Firms and Its Dynamic Behavior in Start-Up Phases.- 2. 1 Macro Structure for Entrepreneurial Management of Start-Ups.- 2.1.1 System Dynamics as Research Methodology.- 2.1.2 Advancement of a Novel Disease Target Technology as Phase Objective.- 2.1.3 Impacts of Entrepreneurial Confidence on Voluntary Leaving, Absorptive Capacity, and Corporate Planning Horizon.- 2.2 Micro Structure that Determines High-Technology Performance.- 2.2.1 Average Research Experience of Scientists.- 2.2.2 Diversity of Scientific Disciplines.- 2.2.3 Research Quality as Dependent on Understanding of Failures.- 2.3 Dynamic Behavior from Start-Up Model Experiments.- 2.3.1 Surprise Behavior of Technology Effectiveness.- 2.3.2 Start-Up Success as Determined by Conditions of Corporate Foundation.- 2.3.3 Policy Design to Accelerate Start-Up Success.- 3 Model Structure and Dynamic Behavior for High-Technology Firms in Transition to Growth Phases.- 3. 1 Macro Structure for Contract Research.- 3.1.1 Scope of Transition Model, Boundaries, and Time Horizon.- 3.1.2 Feedback Structures for Growth and Growth Saturation.- 3.1.3 Principal-Agent Theory to Investigate Research Contracts.- 3.2 Micro Structure for Contract Research on Novel Disease Targets.- 3.2.1 Industry Demand for Research Contracts.- 3.2.2 Planning of Scientific Laboratory Personnel.- 3.2.3 Obsolescence/Irrelevance of Scientific Experience and Contract Research Funding.- 3.3 Dynamic Behavior from Transition Model Experiments.- 3.3.1 Simulation Studies on Corporate Transition.- 3.3.2 Attractive ness Fluctuations from Technology Effectiveness.- 3.3.3 Firm Value from Contract Research Funds.- 4 Economic Value Creation in Transition Phases: Access to Equity Capital.- 4. 1 Value Creation from Drug Candidates in Collaborative R&D Pipelines.- 4.1.1 Flow of Drug Candidates Through Pipeline Phases.- 4.1.2 Present Value of Royalty Expectations from Drug Candidates.- 4.1.3 Capital Asset Pricing Model for Discount Rate Estimation.- 4.2 Simulation of Value Creation.- 4.2.1 Present Values of Pipeline Phases.- 4.2.2 Option Premium as a Complement to Present Value.- 4.2.3 Option Premium and Present Value for Investment Decisions.- 4.3 Equity Financing for Growth Phases.- 4.3.1 Fund-Raising Success as Determine by Value Creation in R&D.- 4.3.2 Attractiveness to Investors from Research Track Record and Collaborative Partnership.- 4.3.3 Sensitivity of Fund-Raising Success to Value Creation in R&D.- 5 Strategies for Growth Phases to Sustain Independence.- Appendix 1: Parameter List for Start-Up Model.- Appendix 2: List of Equations for Start-Up Model.- Appendix 3: Parameter List for Transition Model.- Appendix 4: A Dynamic Theory on Cost of Capital for Biotechnology Firms." @default.
- W629160261 created "2016-06-24" @default.
- W629160261 creator A5087457780 @default.
- W629160261 date "2003-03-11" @default.
- W629160261 modified "2023-09-27" @default.
- W629160261 title "Entrepreneurship in Biotechnology: Managing for Growth from Start-Up to Initial Public Offering" @default.
- W629160261 hasPublicationYear "2003" @default.
- W629160261 type Work @default.
- W629160261 sameAs 629160261 @default.
- W629160261 citedByCount "1" @default.
- W629160261 crossrefType "book" @default.
- W629160261 hasAuthorship W629160261A5087457780 @default.
- W629160261 hasConcept C10138342 @default.
- W629160261 hasConcept C144133560 @default.
- W629160261 hasConcept C199360897 @default.
- W629160261 hasConcept C2778012447 @default.
- W629160261 hasConcept C28761237 @default.
- W629160261 hasConcept C40700 @default.
- W629160261 hasConcept C41008148 @default.
- W629160261 hasConcept C84309077 @default.
- W629160261 hasConceptScore W629160261C10138342 @default.
- W629160261 hasConceptScore W629160261C144133560 @default.
- W629160261 hasConceptScore W629160261C199360897 @default.
- W629160261 hasConceptScore W629160261C2778012447 @default.
- W629160261 hasConceptScore W629160261C28761237 @default.
- W629160261 hasConceptScore W629160261C40700 @default.
- W629160261 hasConceptScore W629160261C41008148 @default.
- W629160261 hasConceptScore W629160261C84309077 @default.
- W629160261 hasLocation W6291602611 @default.
- W629160261 hasOpenAccess W629160261 @default.
- W629160261 hasPrimaryLocation W6291602611 @default.
- W629160261 hasRelatedWork W1904973655 @default.
- W629160261 hasRelatedWork W2013688032 @default.
- W629160261 hasRelatedWork W2015074958 @default.
- W629160261 hasRelatedWork W2134347116 @default.
- W629160261 hasRelatedWork W2134988500 @default.
- W629160261 hasRelatedWork W2135145551 @default.
- W629160261 hasRelatedWork W2365982175 @default.
- W629160261 hasRelatedWork W2386928228 @default.
- W629160261 hasRelatedWork W248559048 @default.
- W629160261 hasRelatedWork W2500177215 @default.
- W629160261 hasRelatedWork W2508908586 @default.
- W629160261 hasRelatedWork W2767263287 @default.
- W629160261 hasRelatedWork W2909500697 @default.
- W629160261 hasRelatedWork W2998481356 @default.
- W629160261 hasRelatedWork W3114982195 @default.
- W629160261 hasRelatedWork W3121233609 @default.
- W629160261 hasRelatedWork W3179755814 @default.
- W629160261 hasRelatedWork W3197112294 @default.
- W629160261 hasRelatedWork W3199750761 @default.
- W629160261 hasRelatedWork W3206549939 @default.
- W629160261 isParatext "false" @default.
- W629160261 isRetracted "false" @default.
- W629160261 magId "629160261" @default.
- W629160261 workType "book" @default.